EGFRChannel | OncLive®

TOP 5 HIGHLIGHTS FROM AACR 2026

HS-10504 in *EGFR* C797S–Mutant NSCLC

Fourth-Gen TKI Shows 50% ORR After Osimertinib Resistance

ORR 50%, DCR ~91% at 400 mg in post-TKI C797S–mutant NSCLC

C797S is the primary acquired resistance mechanism to osimertinib — and a major unmet need.

Caroline Seymour · HS-10504 Shows Promising Activity in *EGFR* C797S-Mutant NSCLC After TKI Resistance

Amivantamab + Lazertinib: Second-Line PFS Data (MARIPOSA)

First-Line Ami/Laz Combo Extends Second-Line PFS vs Osimertinib

Median 2L PFS 8.4 mo vs 5.3 mo (HR, 0.72) at 37.9-month follow-up

Post hoc MARIPOSA analysis reinforces sequencing advantage of the FDA-approved combination.

Caroline Seymour · Amivantamab Plus Lazertinib Extends Second-Line PFS in *EGFR*-Mutant Advanced NSCLC

VRN110755 in *EGFR*-Mutant NSCLC

Next-Gen TKI Demonstrates Early Antitumor Activity Across All Dose Levels

Clinically meaningful responses in heavily pretreated patients across doses up to 240 mg

CNS activity and potency against acquired resistance mutations differentiate VRN110755 from earlier-generation TKIs.

Courtney Flaherty · VRN110755 Shows Initial Antitumor Activity Across Dose Levels in *EGFR*-Mutant NSCLC

SC 3613 in *EGFR*-Mutant NSCLC

Novel Agent Shows Potent AntiTumor Activity With Tolerable Safety Signal

Early-phase data support a favorable tolerability profile alongside antitumor activity

Emerging candidate targeting EGFR-driven disease with a differentiated safety approach.

Ashling Wahner · SC3613 Shows Potent Antitumor Activity and Potential for Tolerable Safety in *EGFR*-Mutant NSCLC Cells

EPI-326: Preclinical Data Support EGFR-Resistant Tumors

Preclinical Evidence Supports Clinical Advancement in EGFR-Resistant NSCLC

Preclinical findings demonstrate targeted activity in EGFR-resistant tumor models

1Early-stage data pave the way for first-in-human investigation.

Chris Ryan · Preclinical Data for EPI-326 Support Clinical Research in EGFR-Responsive Solid Tumors